Lexicon Current Deferred Revenue vs Non Currrent Assets Other Analysis

LXRX Stock

USD 0.80 0.02 2.44%

Lexicon Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Lexicon Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexicon Pharmaceuticals is a good investment. Please check the relationship between Lexicon Pharmaceuticals Current Deferred Revenue and its Non Currrent Assets Other accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Current Deferred Revenue vs Non Currrent Assets Other

Current Deferred Revenue vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexicon Pharmaceuticals Current Deferred Revenue account and Non Currrent Assets Other. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Lexicon Pharmaceuticals' Current Deferred Revenue and Non Currrent Assets Other is 0.13. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Lexicon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Lexicon Pharmaceuticals' Current Deferred Revenue and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Lexicon Pharmaceuticals are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Current Deferred Revenue i.e., Lexicon Pharmaceuticals' Current Deferred Revenue and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Lexicon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexicon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.At this time, Lexicon Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 145.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.71) in 2024.

	2023	2024 (projected)
Extraordinary Items	3.6M	3.2M
Reconciled Depreciation	510K	484.5K

Extraordinary Items Reconciled Depreciation

Lexicon Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Assets
Total Assets		0.43	0.23	0.68	0.39	0.36	0.51	-0.57	-0.11	0.47	0.84	0.74	0.13	0.98	0.18	-0.05	0.88	0.72	0.45	0.13	0.78	0.3	0.98	0.33	0.53	-0.39
Short Long Term Debt Total	0.43		0.39	0.46	-0.2	-0.08	0.24	0.35	-0.34	0.54	0.18	0.21	-0.16	0.39	0.57	0.13	0.5	0.9	0.0	-0.39	0.83	-0.14	0.45	0.11	0.25	-0.23
Other Current Liab	0.23	0.39		0.54	-0.12	-0.37	0.6	0.2	-0.31	0.27	0.02	-0.22	-0.2	0.28	0.66	0.21	0.43	0.3	0.07	-0.14	0.42	-0.43	0.35	-0.05	0.14	-0.14
Total Current Liabilities	0.68	0.46	0.54		0.31	-0.02	0.82	-0.37	-0.18	0.86	0.65	0.3	-0.13	0.74	0.16	0.05	0.8	0.58	0.09	0.17	0.8	-0.09	0.73	0.28	0.25	-0.29
Total Stockholder Equity	0.39	-0.2	-0.12	0.31		0.2	0.12	-0.55	0.31	0.18	0.48	0.24	-0.2	0.44	-0.35	-0.18	0.35	-0.02	0.38	0.26	0.1	0.12	0.4	0.45	-0.12	-0.25
Property Plant And Equipment Net	0.36	-0.08	-0.37	-0.02	0.2		-0.22	-0.39	0.41	0.02	0.35	0.77	-0.17	0.22	-0.03	-0.46	0.2	0.19	-0.25	-0.12	0.13	0.98	0.19	0.14	0.13	-0.48
Current Deferred Revenue	0.51	0.24	0.6	0.82	0.12	-0.22		-0.29	-0.43	0.59	0.46	0.03	0.13	0.63	0.09	0.38	0.64	0.36	0.02	0.43	0.57	-0.22	0.61	-0.08	0.35	0.11
Net Debt	-0.57	0.35	0.2	-0.37	-0.55	-0.39	-0.29		-0.33	-0.17	-0.86	-0.49	-0.23	-0.6	0.48	0.43	-0.37	-0.02	-0.39	-0.45	-0.15	-0.35	-0.53	-0.34	-0.16	0.42
Retained Earnings	-0.11	-0.34	-0.31	-0.18	0.31	0.41	-0.43	-0.33		-0.26	0.14	0.0	-0.13	-0.12	-0.06	-0.89	-0.16	-0.22	-0.1	-0.43	-0.23	0.33	-0.13	0.34	-0.75	-0.6
Accounts Payable	0.47	0.54	0.27	0.86	0.18	0.02	0.59	-0.17	-0.26		0.49	0.31	-0.24	0.49	0.04	0.09	0.65	0.56	-0.07	0.21	0.73	-0.02	0.47	0.24	0.25	-0.18
Cash	0.84	0.18	0.02	0.65	0.48	0.35	0.46	-0.86	0.14	0.49		0.63	0.13	0.86	-0.21	-0.35	0.69	0.52	0.43	0.26	0.62	0.27	0.82	0.39	0.31	-0.55
Non Current Assets Total	0.74	0.21	-0.22	0.3	0.24	0.77	0.03	-0.49	0.0	0.31	0.63		-0.08	0.6	-0.06	-0.17	0.53	0.52	0.17	0.04	0.5	0.74	0.58	0.19	0.56	-0.39
Non Currrent Assets Other	0.13	-0.16	-0.2	-0.13	-0.2	-0.17	0.13	-0.23	-0.13	-0.24	0.13	-0.08		0.2	-0.1	0.1	-0.03	-0.11	0.19	0.34	-0.13	-0.06	0.18	0.17	0.21	0.25
Cash And Short Term Investments	0.98	0.39	0.28	0.74	0.44	0.22	0.63	-0.6	-0.12	0.49	0.86	0.6	0.2		0.13	-0.01	0.89	0.67	0.47	0.21	0.77	0.16	0.99	0.33	0.47	-0.34
Net Receivables	0.18	0.57	0.66	0.16	-0.35	-0.03	0.09	0.48	-0.06	0.04	-0.21	-0.06	-0.1	0.13		-0.01	0.3	0.41	-0.09	-0.55	0.36	-0.08	0.23	0.13	0.04	-0.23
Common Stock Shares Outstanding	-0.05	0.13	0.21	0.05	-0.18	-0.46	0.38	0.43	-0.89	0.09	-0.35	-0.17	0.1	-0.01	-0.01		0.07	0.02	-0.01	0.4	0.03	-0.36	-0.01	-0.48	0.49	0.84
Short Term Investments	0.88	0.5	0.43	0.8	0.35	0.2	0.64	-0.37	-0.16	0.65	0.69	0.53	-0.03	0.89	0.3	0.07		0.71	0.3	0.14	0.82	0.16	0.9	0.18	0.38	-0.27
Non Current Liabilities Total	0.72	0.9	0.3	0.58	-0.02	0.19	0.36	-0.02	-0.22	0.56	0.52	0.52	-0.11	0.67	0.41	0.02	0.71		0.1	-0.3	0.95	0.12	0.7	0.1	0.35	-0.37
Other Current Assets	0.45	0.0	0.07	0.09	0.38	-0.25	0.02	-0.39	-0.1	-0.07	0.43	0.17	0.19	0.47	-0.09	-0.01	0.3	0.1		0.29	0.11	-0.32	0.49	0.31	0.32	-0.15
Other Stockholder Equity	0.13	-0.39	-0.14	0.17	0.26	-0.12	0.43	-0.45	-0.43	0.21	0.26	0.04	0.34	0.21	-0.55	0.4	0.14	-0.3	0.29		-0.16	-0.04	0.15	-0.02	0.48	0.4
Total Liab	0.78	0.83	0.42	0.8	0.1	0.13	0.57	-0.15	-0.23	0.73	0.62	0.5	-0.13	0.77	0.36	0.03	0.82	0.95	0.11	-0.16		0.06	0.79	0.17	0.35	-0.38
Property Plant And Equipment Gross	0.3	-0.14	-0.43	-0.09	0.12	0.98	-0.22	-0.35	0.33	-0.02	0.27	0.74	-0.06	0.16	-0.08	-0.36	0.16	0.12	-0.32	-0.04	0.06		0.13	0.05	0.18	-0.33
Total Current Assets	0.98	0.45	0.35	0.73	0.4	0.19	0.61	-0.53	-0.13	0.47	0.82	0.58	0.18	0.99	0.23	-0.01	0.9	0.7	0.49	0.15	0.79	0.13		0.34	0.47	-0.35
Short Term Debt	0.33	0.11	-0.05	0.28	0.45	0.14	-0.08	-0.34	0.34	0.24	0.39	0.19	0.17	0.33	0.13	-0.48	0.18	0.1	0.31	-0.02	0.17	0.05	0.34		-0.04	-0.52
Common Stock	0.53	0.25	0.14	0.25	-0.12	0.13	0.35	-0.16	-0.75	0.25	0.31	0.56	0.21	0.47	0.04	0.49	0.38	0.35	0.32	0.48	0.35	0.18	0.47	-0.04		0.16
Other Assets	-0.39	-0.23	-0.14	-0.29	-0.25	-0.48	0.11	0.42	-0.6	-0.18	-0.55	-0.39	0.25	-0.34	-0.23	0.84	-0.27	-0.37	-0.15	0.4	-0.38	-0.33	-0.35	-0.52	0.16

Click cells to compare fundamentals

Lexicon Pharmaceuticals Account Relationship Matchups

Lexicon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	417.7M	203.8M	136.9M	194.3M	229.4M	326.8M
Short Long Term Debt Total	246.3M	12.8M	2.3M	55.3M	106.1M	76.2M
Other Current Liab	42.2M	29.1M	11.9M	11.5M	15.9M	12.8M
Total Current Liabilities	65.3M	46.8M	22.1M	23.2M	31.5M	48.4M
Total Stockholder Equity	(1.3B)	156.4M	(1.5B)	(1.6B)	93.1M	97.8M
Property Plant And Equipment Net	14.0M	295K	1.2M	2.1M	7.5M	7.1M
Net Debt	210.2M	(113.5M)	(61.8M)	8.9M	83.6M	87.8M
Retained Earnings	(1.3B)	(1.4B)	(1.5B)	(1.6B)	(1.8B)	(1.7B)
Accounts Payable	12.2M	5.5M	9.2M	10.4M	14.4M	13.3M
Cash	36.1M	126.3M	64.1M	46.3M	22.5M	21.3M
Non Current Assets Total	80.0M	46.1M	48.0M	53.4M	52.9M	104.9M
Non Currrent Assets Other	1.7M	1.2M	2.3M	6.8M	828K	786.6K
Cash And Short Term Investments	271.7M	152.3M	86.7M	138.4M	170.0M	206.8M
Net Receivables	56.5M	395K	14K	28K	1.0M	959.5K
Common Stock Shares Outstanding	116.7M	110.8M	145.7M	165.7M	221.1M	232.2M
Short Term Investments	235.5M	26.0M	22.7M	92.0M	147.6M	137.0M
Liabilities And Stockholders Equity	(1.0B)	203.8M	(1.5B)	(1.5B)	229.4M	240.9M
Non Current Liabilities Total	235.3M	611K	1.2M	54.0M	104.8M	100.6M
Other Current Assets	5.3M	10.1M	4.3M	2.5M	5.1M	7.0M
Other Stockholder Equity	(190K)	1.6B	1.6B	1.7B	1.9B	941.0M
Total Liab	300.6M	47.4M	23.3M	77.2M	136.3M	149.0M
Property Plant And Equipment Gross	14.0M	295K	6.0M	12.9M	12.0M	11.4M
Total Current Assets	337.8M	157.7M	88.9M	140.9M	176.5M	221.8M
Accumulated Other Comprehensive Income	84K	(6K)	(10K)	(428K)	31K	32.6K
Short Term Debt	11.0M	12.2M	1.1M	1.3M	1.2M	1.1M
Other Assets	285K	(45K)	1.2M	136.9M	157.4M	165.3M
Long Term Debt	231.6M	243.9M	234.2M	48.6M	99.5M	77.2M
Property Plant Equipment	14.0M	295K	1.2M	2.1M	1.9M	1.8M
Other Liab	29.9M	55.4M	35.8M	23.3M	26.8M	43.1M
Treasury Stock	(3.8M)	(4.8M)	(7.5M)	(2.1M)	(1.9M)	(1.9M)
Net Tangible Assets	52.8M	111.8M	69.1M	72.6M	65.3M	67.6M
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.5B)	(1.6B)	(1.4B)	(1.5B)
Capital Surpluse	1.5B	1.6B	1.6B	1.7B	2.0B	1.5B
Inventory	1.9M	4.7M	4.2M	1.0	381K	362.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexicon Current Deferred Revenue vs Non Currrent Assets Other Analysis

Current Deferred Revenue vs Non Currrent Assets Other

Current Deferred Revenue vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Non Currrent Assets Other

Lexicon Pharmaceuticals fundamental ratios Correlations

Lexicon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lexicon Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Lexicon Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.95	Non Current Liabilities Total
Non Current Liabilities Total	+ 0.9	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.89	Retained Earnings
Cash	- 0.86	Net Debt
Common Stock	- 0.75	Retained Earnings
Other Assets	- 0.6	Retained Earnings
Cash And Short Term Investments	- 0.6	Net Debt
Net Debt	- 0.57	Total Assets